United States Patent 12,083,112 (PD-1 pembrolizumab + lenvatinib multi-RTK inhibitor in thyroid/HCC/RCC/endometrial/HNSCC/glioblastoma/gastric cancer/melanoma): Scope, claim-by-claim IP boundaries, and US patent landscape
What is US Patent 12,083,112 and what does it claim?
US12,083,112 claims methods and kits for treating specific cancers using a combination therapy in which:
- the PD-1 antagonist is pembrolizumab, and
- the multi-RTK inhibitor is lenvatinib (or a pharmaceutically acceptable salt),
- with claim variations covering order of administration, timing, cancer type, dosing schedules, PD‑L1 IHC status, and product formats (including a specified pembrolizumab liquid composition and lenvatinib capsule excipients).
High-level claim architecture (from the provided claim set)
- Independent claims: claim 1 (method) and claim 6 (kit). Claim 11 adds a dosing-duration dependent method limitation.
- Dependent claims narrow: human subject, treatment sequencing, at-least-7-day lead-in, PD‑L1 IHC positive instruction, specific pembrolizumab formulation and lenvatinib capsule excipient profile, cancer subtypes, and dose regimens.
Core coverage theme
The patent is drafted to create multiple infringement entry points:
- Clinical protocol infringement (treatment sequencing + cancer indications + dosing).
- Label/instructions infringement via kit packaging instructions (including PD‑L1 IHC status).
- Formulation/product infringement via claimed compositions and capsule excipient sets (pembrolizumab liquid and lenvatinib capsule components).
What is the effective scope of Claim 1 (method for treating cancer with pembrolizumab + lenvatinib)?
Claim 1 is the broadest method claim provided.
Claim 1 key elements
- “A method for treating a cancer” in an individual
- Administer a combination therapy comprising:
- PD-1 antagonist = pembrolizumab
- multi‑RTK inhibitor = lenvatinib (or salt)
- Cancer limited to:
- thyroid cancer
- HCC
- RCC
- endometrial cancer
- squamous cell carcinoma of head and neck
- glioblastoma
- gastric cancer
- melanoma
Practical enforcement boundary
Claim 1 captures “any” administration of the two drugs together for the listed cancers, even if the regimen is not specified in claim 1 (dose and frequency are delegated to dependent claims). That makes claim 1 the anchor for protocol-based litigation and for “on-label” and “off-label” exposure, depending on proof of administration.
How do the “order and timing” dependent claims (3–5) narrow infringement risk windows?
Claim 3
Combination therapy is administered after an administration of lenvatinib.
Claim 4
Same as claim 3, but adds: lenvatinib lead-in for at least 7 days before starting pembrolizumab + lenvatinib combination.
Claim 5
Combination therapy is administered after an administration of pembrolizumab (a reversal option relative to claims 3–4).
Implication for scope
- These dependents let the patentee argue infringement under specific treatment sequencing.
- If an accused regimen uses simultaneous start with neither drug first, claim 1 may still read if “combination therapy” is interpreted broadly enough, but claims 3–4 create stronger causation and protocol alignment if a real-world protocol uses a lead-in.
What does Claim 6 (kit claim) cover, and why it matters for manufacturing and label-infringement?
Claim 6 is a kit claim that requires:
- First container with at least one dose of a PD‑1 antagonist medicament where:
- PD‑1 antagonist is pembrolizumab
- Second container with at least one dose of a multi‑RTK inhibitor medicament where:
- multi‑RTK inhibitor is lenvatinib (salt allowed)
- Package insert with instructions for treating cancer using the medicaments, consistent with the combination
- The kit concept ties infringement to packaging, instructions, and product configuration, not only physician administration.
Kit enforcement vectors
- Paragraph IV / generic or biosimilar challenges can be affected if the kit instructions are required for the method claim pathways.
- A label or Instructions for Use (IFU) that matches claim language can support inducement theories where direct administration is performed by a provider.
How do Claim 7 and PD‑L1 IHC positivity limit the kit instructions?
Claim 7 narrows: instructions state intended use for cancer that tests positive for PD‑L1 expression by IHC assay.
Scope effect
- This dependent claim can be relevant if an accused kit’s instructions explicitly require PD‑L1 IHC positivity.
- If a competing label does not include the PD‑L1 IHC criterion, claim 7 is harder to fit, but independent claim 6 may still be targeted depending on the overall instructions content.
What product/formulation scope is locked by Claim 9 (pembrolizumab liquid + lenvatinib capsule excipients)?
Claim 9 adds a specific formulation and excipient profile for both components.
Pembrolizumab liquid medicament parameters (as claimed)
- 25 mg/mL pembrolizumab
- 7% (w/v) sucrose
- 0.02% (w/v) polysorbate 80
- 10 mM histidine buffer pH 5.5
Lenvatinib capsule (as claimed)
- 4 mg or 10 mg lenvatinib capsule
- Excipient set includes:
- calcium carbonate
- mannitol
- microcrystalline cellulose
- hydroxypropylcellulose
- low‑substituted hydroxypropylcellulose
- talc
Scope effect
- Claim 9 is a comparatively more constrained dependent claim because it ties to specific formulation composition features. This is the type of dependent claim that can be used to attack generic product sameness (composition and formulation) where there is evidence of close matching.
- It does not replace claim 1 or 6; it adds an additional infringement hook.
How does Claim 10 expand the cancer list in the kit context (including NSCLC vs claim 1)?
Claim 10 includes:
- thyroid cancer, HCC, NSCLC, RCC, endometrial cancer, squamous cell carcinoma of head and neck, glioblastoma, melanoma.
Difference vs claim 1
- Claim 1 includes gastric cancer.
- Claim 10 includes NSCLC.
So the kit claim cancer coverage is not identical to the method claim cancer coverage.
What does Claim 11 require (24-week combination + specific doses and schedule)?
Claim 11 is a protocol-and-duration dependent method claim:
- Treat a human individual
- Administer combination therapy for at least 24 weeks
- Pembrolizumab + lenvatinib regimen:
- Lenvatinib daily dose: 24 mg, 20 mg, or 14 mg
- Pembrolizumab dose: 200 mg once every three weeks
Claims 12 and 13
- Claim 12: lenvatinib dose options (24/20/14 mg)
- Claim 13: pembrolizumab 200 mg Q3W
Claims 14–21
Cure target cancer type narrowing for each listed cancer.
Scope effect
Claim 11 supplies a highly specific real-world protocol (dose + Q3W schedule + 24-week duration). That tends to:
- strengthen enforceability against defendants aligned with that specific regimen,
- reduce risk of overbreadth defenses.
How many infringement paths exist based on these claims?
Based on only the claim set provided, at least four independent infringement pathways exist:
- Method (Claim 1): administration of pembrolizumab + lenvatinib for the enumerated cancers.
- Method sequencing (Claims 3–5): start order and lead-in timing create additional fit points.
- Duration and dosing protocol (Claim 11 + 12–13): at least 24 weeks, lenvatinib 14/20/24 mg, pembrolizumab 200 mg Q3W.
- Kit and instructions (Claims 6–8, 10): packaging + IFU consistent with treating specified cancers; PD‑L1 IHC positive instruction (Claim 7); includes defined formulation/product composition (Claim 9).
What is the US patent landscape around PD‑1 pembrolizumab + lenvatinib combination therapy?
Landscape structure you should model
For a combination regimen like pembrolizumab + lenvatinib, US exclusivity and patentability typically cluster into:
- Composition-of-matter patents for each drug (pembrolizumab and lenvatinib) held by their respective innovators.
- Combination method-of-treatment patents (like this one).
- Dosing regimen patents (dose, frequency, sequence, cycle length, duration).
- Biomarker patents (PD‑L1 IHC, prognostic/predictive signatures, enriched subgroups).
- Formulation patents (specific liquids for antibodies, capsule excipient sets, buffer/pH/sucrose/polysorbate constraints).
- Manufacturing and kit logistics (separate containers with instructions).
Because US12,083,112 is drafted with multiple dependent claim hooks, it behaves as a “combination platform” patent rather than a single narrow regimen claim.
What patents protect the same clinical space as US12,083,112 in the United States?
A complete, accurate cross-patent comparison requires the Orange Book and patent-family data for the relevant FDA approvals (pembrolizumab and lenvatinib labels and the combination indications). That information is not provided in the prompt, so a complete landscape cannot be produced.
When does US12,083,112 lose enforceability (expiration, exclusivity, terminal disclaimers)?
A reliable enforceability timeline requires the patent’s filing date, priority date, prosecution history (terminal disclaimer), and term adjustments. Those data are not provided in the prompt, so an accurate expiration analysis cannot be completed.
How strong is the patent estate for generic or biosimilar entry against the combination?
Strength drivers (from the provided claim scope)
- Multiple cancer indications in one claim family increases the number of clinical uses that can be accused.
- Multiple dependent hooks (sequence timing, PD‑L1 IHC instructions, kit packaging, specific dosing and 24-week duration) reduce “workaround” freedom.
- Kit + instructions claim increases leverage against label-matching generic strategies.
- Formulation-dependent claim can affect product design-around feasibility.
Weakness drivers (structural, not speculative)
- Claims 9 and 7 are narrower and depend on matching specific formulation attributes and PD‑L1 IHC instruction language.
- Claim scope relies on proper mapping of accused treatment to the enumerated cancers and regimen timing/duration, where those elements are only included in dependent claims.
Which generic entry risks exist for pembrolizumab + lenvatinib combinations under this patent?
Small-molecule generics (lenvatinib)
A lenvatinib generic can be launched without solving the method-of-treatment infringement risk if the combination and regimen are used in the covered cancer indications. The patent still targets “administering” and “kits with instructions.”
Antibody biosimilars (pembrolizumab)
For biosimilars, even if the biosimilar is highly similar, the method claim language can still be satisfied if the accused therapy uses a PD‑1 antagonist equivalent that is literally pembrolizumab. Literal infringement requires the claimed PD‑1 antagonist to be pembrolizumab per the provided claim set.
But the kit claim and method claim text you provided is explicit: PD‑1 antagonist is pembrolizumab. That limits doctrinal scope to pembrolizumab unless the patent language otherwise includes equivalents (not shown in the excerpt).
How does this patent compare with typical pembrolizumab combo patents (what it adds)?
From the claim text alone, US12,083,112 is more demanding than some combination patents because it:
- spans many cancers in one claim,
- includes sequencing and minimum lead-in timing options (≥7 days for lenvatinib before combination),
- includes 24-week treatment duration and exact Q3W pembrolizumab dosing in claim 11,
- includes a defined antibody liquid composition and specific capsule excipient set in claim 9.
Key Takeaways
- US12,083,112 targets a pembrolizumab (PD‑1) + lenvatinib (multi‑RTK) combination for a defined list of cancers in the US.
- Independent coverage is split between method (Claim 1) and kit (Claim 6), with dependent claims adding sequence, lead-in timing (≥7 days), PD‑L1 IHC positive instructions (Claim 7), specific formulations (Claim 9), and a highly specific dosing-duration protocol (Claim 11: ≥24 weeks; lenvatinib 14/20/24 mg daily; pembrolizumab 200 mg Q3W).
- The claim set provides multiple infringement hooks: clinical protocol, product/label kit instructions, and composition/formulation limitations.
FAQs
-
Does US12,083,112 require PD‑L1 positivity to infringe?
Not for Claim 1 or Claim 6 as presented; PD‑L1 IHC positivity is explicitly required only in dependent Claim 7.
-
Can a different dosing schedule avoid infringement?
Claim 1 does not specify dose, so a different schedule may still fall within Claim 1 if “combination therapy” is administered for the enumerated cancers. Avoidance is more plausible only for dependent claims that require specific dosing/duration (notably Claim 11).
-
What is the significance of the ≥7-day lenvatinib lead-in?
It is explicitly required for Claim 4. Regimens that do not include that lead-in align less cleanly with Claims 3–4.
-
Is a kit claim broader than a method claim for enforcement?
A kit claim can be powerful where packaging and instructions mirror the claim, but it is still limited to kits meeting the claim’s container and insert requirements and any dependent instructions/formulation constraints.
-
Does Claim 9 require the accused products to match the stated pembrolizumab liquid and lenvatinib capsule excipient compositions?
Yes, Claim 9 as provided is composition- and excipient-specific, so matching those defined parameters is required for that dependent hook.
References
- United States Patent 12,083,112 (claims provided in prompt).
